Amgen Loses Bid To Wrap Up Teva Patent Fight

Law360, New York (November 22, 2010, 5:28 PM EST) -- Pharmaceutical giant Amgen Inc. has lost its bid for partial summary judgment in a patent spat launched by Teva Pharmaceuticals USA Inc. as part of its effort to market a generic version of Amgen's blood drug Neupogen.

Judge Stewart Dalzell issued his order in the U.S. District Court for the Eastern District of Pennsylvania on Friday, denying both Amgen's bid for partial summary judgment and Teva's motion to file a second amended complaint.

Israeli generic-drug maker Teva lodged the suit in November 2009 after seeking approval...
To view the full article, register now.